During the past decade, Legacy Research Institute conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 8 clinical trials were completed, i.e. on average, 133.3% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 4 clinical trials were completed. i.e. 200% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Legacy Research Institute" #1 sponsor was "AstraZeneca" with 3 trials, followed by "Mannkind Corporation" with 3 trials sponsored, "FibroGen" with 2 trials sponsored, "Legacy Health System" with 2 trials sponsored and "Novartis Pharmaceuticals" with 2 trials sponsored. Other sponsors include 6 different institutions and companies that sponsored additional 15 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Legacy Research Institute" #1 collaborator was "Juvenile Diabetes Research Foundation" with 2 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator, "International Maternal Pediatric Adolescent AIDS Clinical Trials Group" with 1 trials as a collaborator, "Jaeb Center for Health Research" with 1 trials as a collaborator and "Oregon Health and Science University" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "Legacy Research Institute" are "Pulmonary Arterial Hypertension" (3 trials), "Type 2 Diabetes" (3 trials), "Idiopathic Pulmonary Fibrosis" (2 trials), "Type 1 Diabetes" (2 trials) and "Acute Coronary Syndrome" (1 trials). Many other conditions were trialed in "Legacy Research Institute" in a lesser frequency.

Most popular intervention types in "Legacy Research Institute" are "Drug" (18 trials), "Device" (3 trials), "Diagnostic Test" (1 trials), "Other" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (7 trials), "AC2993" (3 trials), "Pamrevlumab" (2 trials), "placebo" (2 trials) and "Active comparator" (1 trials). Other intervention names were less common.

The vast majority of trials in "Legacy Research Institute" are 23 trials for "All" genders.

Currently, there are NaN active trials in "Legacy Research Institute". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 15 completed trials in Legacy Research Institute, 1 suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Legacy Research Institute, 0 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 13 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".